Wang DY, Moorhadian MC, Kim D, Shah NJ, Fenton SE, Conry RM, Mehta R, Silk  AW, Zhou A, Compton ML, Al-Rohil RN, Lee S, Voorhees AL, Ha L, Mckee S, Norrell  JT, Mehnert J, Puzanov I, Sosman JA, Chandra S, Gibney GT, Rapisuwon S, Eroglu Z,  Sullivan Z, Sullivan R, Johnson DB. Clinical characterization of colitis arising from  anti-PD-1 based therapy. Oncoimmunology. 2018, Oct PMCID:30546965 

Shah NJ, Al-Shbool G, Blackburn M, Cook M, Belouali A, Liu SV, Madhavan S, He  AR, Atkins MB, Gibney GT, Kim C. Safety and efficacy of immune checkpoint  inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. Journal for ImmunoTherapy of Cancer. 2019, Dec;7:353. PMCID: PMC6918622 

Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC,  Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI. Salvage Ipilimumab and  Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune  Checkpoint Inhibitors. J Clin Oncol. 2020,Sep PMCID:32491962 

Gupta S, Belouali A, Shah NJ, Atkins MB, Madhavan S. Automated identification of  patients with immune-related adverse events from clinical notes using word embedding  and machine learning. JCO Clinical Cancer Informatics. 2021, Jan;5:541-549. PMCID:  PMC8462565 

Baldelli E, Hodge KA, Bellezza G, Shah NJ, Gambara G, Sidoni A, Mandarano M,  Ruhunusiri C, Dunetz B, Abu-Khalaf M, Wulfkuhle J, Gallagher RI, Liotta L, Bono JD,  Mehra N, Riisnaes R, Ravaggi A, Odicino F, Sereni AI, Blackburn M, Zupa A, Improta  G, Demsko P, Crino L, Ludovini V, Gioccone G, Petricoin EF, Pierobon M. PD-L1  quantification across tumor types using the reverse phase protein microarray:  implications for precision medicine. Journal for Immunother Cancer.  2021,Oct PMCID:34620701 

Shah NJ, Zhang D, Cook M, Blackburn M, Serzan MT, Advani S, Potosky AL, Atkins  MB, Braithwaite D. Association between Body Mass Index and Immune-Related  Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune  Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers. 2021, Dec PMCID:8657283 

Shah NJ, Cook MR, Wu T, Lev-Ari S, Blackburn MJ, Serzan MT, Alaoui A, Ahn J,  Atkins MB. The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis  in Patients on Checkpoint Inhibitors Requiring Steroids. J Natl Compr Canc  Netw. 2022, Jul;7. PMID: 35830888

Shaked Lev-Ari MD, Michael Serzan MD, Tianmin Wu MS, Andrew Ip MD, Lauren Pascual HSD, Brittany Sinclaire MS, Shari Adams HSD, Michael Marafelias BS, Lakshmi Ayyagari MD, Sarvarinder K. Gill MD, Barbara Ma MD, Jacob P. Zaemes MD, Alexandra Della Pia PharmD, Adil Alaoui MS, Subha Madhavan PhD, Anas Belouali MS, Andrew Pecora MD, Jaeil Ahn PhD, Michael B. Atkins MD, Neil J. Shah MD. The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study

Zhang Y, Ari SL, Gupta S, Zaemes J, Shah NJ, Alaoui A, Madhavan S, McGarvey P, Atkins MB. Enhancing patient safety in melanoma treatment: harnessing machine learning for predicting immune-related adverse events. Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1317

Zaemes J, Ari SL, Pascual L, Jegede OA, Arias-Orozco N, Sinclaire B, DellaPia A, Zemel RA, Zhang Y, Gupta S, Alaoui A. Treatment-free survival in patients with advanced melanoma and non-small cell lung cancer receiving immune checkpoint inhibitors: real-world outcomes over a 3-year timespan. Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.1418

Lev-Ari S, Serzan MT, Wu T, Krishnamurthy K, Adams S, Pascual L, Melinda W,  Sinclaire B, Marafelias M, Alaoui A, Ahn J, Pecora A, Ip A, Atkins MB, Shah NJ.  Association of Steroids and Other Immunosuppressive Agents on Efficacy of Immune  checkpoint inhibitor therapy in patients with advanced melanoma. Society for Melanoma  Research (SMR); Virtual, 2021. Oral Presentation  

Ip A, Wang S, Cheruku D, Krishnamurthy K, Weber M, Sinclaire B, Paleoudis EG, Alaoui A, Lev-Ari S, Serzan MT, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Williams A, Ahn J, Pecora A, Atkins MB, Shah NJ. Journal of Clinical  Oncology 2021 39:15_suppl, 2635-2635 

Shah NJ, Wang S, Williams A, Weber M, Sinclaire B, Paleoudis EG, Alaoui A, Lev-Ari  S, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Serzan MT, Cheruku D, Ahn J,  Pecora A, Ip A, Atkins MB. Real-world outcomes of treatment with immune checkpoint  inhibitors in unique patient cohorts: Elderly, non-Caucasian race, poor performance  status, obese, chronic viral infections, and autoimmune diseases. Journal of Clinical  Oncology. 2021, May;39. 

Shah NJ, Al-shbool G, Blackburn M, Cook M, Belouali A, Ochoa S, Colton BS,  Puthiamadathil J, Serzan MT, Knoedler AR, Liu SV, Pishvaian MJ, Mohebtash M,  Madhavan S, He AR, Atkins MB, Gibney GT, Kim C. Safety and efficacy of immune  checkpoint inhibitors (ICIs) in patients with HIV, hepatitis B, or hepatitis C viral  infections. AACR Annual Meeting, Atlanta, 2019, Abstract ID#: 3230 

Belouali A, Shah NJ, Krishnamurthy K, Wang S, Rao S, Gibney GT, Madhavan S,  Atkins MB. A centralized comprehensive immune-oncology repository to enable  outcomes and medication research. 7th Annual Big Data in Biomedicine Symposium at  Georgetown University, Washington, DC, 2018 Abstract ID#: 6  

Kelly WJ, Shah NJ, Serzan MT, Ma BT, Blackburn M, Ochoa S, Knoedler AR,  Puthiamadathil JM, Santopietro A, Madhavan S, Belouali A, Rao S, Gardner KA,  Rapisuwon S, Liu SV, Subramaniam DS, Atkins MB, Gibney GT. Characterization of  Intracranial and Extra-cranial Progression in Patients with Solid Tumor Malignancy with  Brain Metastasis Treated with Immune Checkpoint Inhibitors. 33rd SITCAnnual  Meeting, Washington, DC, 2018.  

Shah NJ, Alsaadi D, Charabaty A, Atkins MB. A Case of Checkpoint Inhibitor -Induced  Celiac Disease. 33rd SITC Annual Meeting, Washington, DC, 2018, Abstract ID#:P447 

Pecora AL, Shah NJ, Jiang S, Atkins MB. Immunotherapy or targeted therapy-initial  therapy for advanced melanoma: a real-world analysis. Society for Melanoma Research  (SMR); Manchester, England, 2018. Abstract ID #:134 

Shah NJ, Puthiamadathil J, Serzan MT et al. Clinical outcome of immune related  hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICIs). ESMO, Munich, Germnay. 2018.  Abstract ID#: 5960 

Shah NJ, Ma BT, Kelly WJ, Belouali A, Serzan MT, Ochoa SG, Colton BS, Janni MM,  Puthiamadathil J, Knoedler AR, Blackburn M, Madhavan S, Kumar PP, Liu SV, Gibney  GT, Atkins MB. Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs). J Clin Oncol 36, 2018,(suppl; abstr e 15074) 

Belouali A, Shah NJ, Rao S, Zhu X, Gibney GT, Madhavan S, Atkins MB. A Cenntralized Comprehensive Immuno-Oncology Repository to enable Outcomes and  Medication Research. 6th Annual Big Data in Biomedicine Symposium at Georgetown  University, Washington, DC Georgetown ICBI 6th Annual Big Data in Biomedicine  Symposium, 2017, Washington, DC 

Shah NJ, Kelly WJ, Ma B, Zhou Y, Puthiamadathil J, Serzan MT, Subramaniam DS,  Giaccone G, Tan MT, Liu SV. Impact of Steroids Use for Immune Related Adverse  Events on Outcomes in Non-Small Cell LungCancer (NSCLC) Treated with Checkpoint  Inhibitors. IASLC, 18th World Conference on Lung Cancer, Yokohama, Japan, 2017. Journal of Thoracic Oncology, 12, 11, S2148 

 Zhang Y, Gupta S, Belouali A, Lev-Ari S, Shah NJ, Krishnamurthy K, Serzan MT, Alaoui A, McGarvey P, Atkins MB, Madhavan S. Prediction of best response for NSCLC patients receiving immunotherapy by machine learning models. J Immunother Cancer 2022;10(Suppl 2):A1–A1603

Derry-Vick H, Zaemes JP, Ahn J, Pascual L, Sinclaire B, Lev-Ari S, Alaoui A, Sridhar A, Adams D, Della Pia A, Pecora AL, Atkins MB, Ip A, Shah NJ. (06/2023). Associations between psychosocial risk factors and immune checkpoint inhibitor outcomes. 2023 American Society of Clinical Oncology Annual Meeting (poster presentation). Chicago, IL.